CANDID THERAPEUTICS

HQ - San Diego, CA

Summary

Candid Therapeutics is focused on developing innovative T-cell engager antibodies to selectively deplete autoreactive B-cells, aiming to transform the treatment of autoimmune diseases with safer and more effective therapies.

Deals Overview

Total Deals1

Valued Deals1

Total Value£ 282 M

Avg. Deal Size£ 282 M

Market Context

Senior Management

Arvind Kush
Chief Financial and Business Officer
Timothy Lu
Chief Medical and Scientific Officer
Bernie Huyghe
CTO

Sort

09 Sep 2024|United States|Biotechnology

Target: TRC 2004

Bidder: CANDID THERAPEUTICS

3 Service Providers

1 Target | 2 Bidder

9 Dealmakers

1 Target | 8 Bidder

£ 281 M

Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy